Genomictree Inc.

228760.KQ

228760.KQGenomictree Inc. KR flag

KOSDAQ

13,190.00

KRW

-80.00

(-0.60%)

316.62BMarket Cap

May 15Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

KR7228760005

Return %

Stock

S&P500

-40.45

12.07

-2.66

62.30

-20.54

98.08

Use logarithmic scale

	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	95.6	14.68	31.77	24.61	14.72	61.97	248.78	1,423.29	152.63	- -	100.78
Basic EPS, GAAP	-112	-55.17	-148.02	-158	-533	-590	-553	-316	-391	- -	-442.1
Free Cash Flow per Basic Share	-92.35	-23.91	-177.88	-308.92	-589.61	-651.5	-941.88	117.31	-498.75	- -	-517.94
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	-164.25	-98.25	-219.25	-102.5	-541.32	-1,116.3	2,739.61	2,406.12	1,932.68	- -	- -
Tangible Book Value per Share	-72.49	78.76	522.86	644	5,634.85	4,716.62	5,471.85	5,044.32	5,522.7	- -	5,118.66
Basic Weighted Avg Shares	11	37	14	16	19	20	21	21	22	- -	24
Sales/Revenue/Turnover	1,049	548	454	387	282	1,239	5,140	29,866	3,418	2,362	2,394
Operating Margin (%)	-69.29	-236.13	-442.36	-665.15	-3,660.22	-1,001.61	-191.75	8.05	-506.24	-648.24	-493.02
Depreciation Expense	98	117	135	188	490	908	1,022	1,335	1,178	1,198	908
Net Income, GAAP	-1,228	-2,061	-2,113	-2,484	-10,195	-11,795	-11,425	-6,631	-8,756	-10,242	-10,502
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Profit Margin (%)	-117.15	-375.84	-465.87	-642.07	-3,619.97	-952.1	-222.28	-22.2	-256.17	-433.57	-438.66
Working Capital	2,565	1,371	5,823	6,511	100,594	101,211	132,185	64,557	90,090	92,912	90,823
LT Debt	- -	- -	- -	400	1,200	11,261	38,179	85	98	60	- -
Total Equity	-389	3,498	8,296	11,085	108,821	95,255	115,101	107,557	125,032	124,320	121,593
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Common Equity (%)	- -	- -	- -	- -	- -	- -	- -	-12.38	-18.68	-26.93	-51.7

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	- -	203.28%	-30.89%
Net Income, GAAP	- -	3.93%	16.98%
Free Cash Flow	- -	-111.32%	44.92%
Total Cash Common Dividend	- -	- -	- -
Total Equity	- -	3.5%	-0.57%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Sung-Whan An
Full Time Employees: 81
Sector: Healthcare
Industry: Biotechnology
Address: 44-6 Techno Daejeon South Korea 34027
IPO Date: Apr 5, 2017
Website: genomictree.com
Similar Companies: Jaguar Health, Inc. (JAGX)
Landos Biopharma, Inc. (LABP)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336.SS)
NDT Pharmaceuticals Inc. (NDTP)
Sorrento Therapeutics, Inc. (SRNE)
Pharming Group N.V. (PHGUF)
Business: Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraTect-KRAS and AccuraTect-BRAF that are companion diagnostics for colorectal cancer; AccuraTect-EGFR, a companion diagnostic for lung cancer; and AccuraDTect SARS-CoV-2 RT-qPCR kits, as well as test providers. Genomictree Inc. was founded in 2000 and is headquartered in Daejeon, South Korea.

	Sep'24	Dec'24	Mar'25
ST Debt	1,945	2,019	- -
LT Borrowings	- -	- -	- -
LT Finance Leases	70	60	- -
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	24	24	- -
Market Capitalization	354,574	477,042	361,548

	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	95.6	14.68	31.77	24.61	14.72	61.97	248.78	1,423.29	152.63	- -	100.78
Basic EPS, GAAP	-112	-55.17	-148.02	-158	-533	-590	-553	-316	-391	- -	-442.1
Free Cash Flow per Basic Share	-92.35	-23.91	-177.88	-308.92	-589.61	-651.5	-941.88	117.31	-498.75	- -	-517.94
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	-164.25	-98.25	-219.25	-102.5	-541.32	-1,116.3	2,739.61	2,406.12	1,932.68	- -	- -
Tangible Book Value per Share	-72.49	78.76	522.86	644	5,634.85	4,716.62	5,471.85	5,044.32	5,522.7	- -	5,118.66
Basic Weighted Avg Shares	11	37	14	16	19	20	21	21	22	- -	24
Sales/Revenue/Turnover	1,049	548	454	387	282	1,239	5,140	29,866	3,418	2,362	2,394
Operating Margin (%)	-69.29	-236.13	-442.36	-665.15	-3,660.22	-1,001.61	-191.75	8.05	-506.24	-648.24	-493.02
Depreciation Expense	98	117	135	188	490	908	1,022	1,335	1,178	1,198	908
Net Income, GAAP	-1,228	-2,061	-2,113	-2,484	-10,195	-11,795	-11,425	-6,631	-8,756	-10,242	-10,502
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Profit Margin (%)	-117.15	-375.84	-465.87	-642.07	-3,619.97	-952.1	-222.28	-22.2	-256.17	-433.57	-438.66
Working Capital	2,565	1,371	5,823	6,511	100,594	101,211	132,185	64,557	90,090	92,912	90,823
LT Debt	- -	- -	- -	400	1,200	11,261	38,179	85	98	60	- -
Total Equity	-389	3,498	8,296	11,085	108,821	95,255	115,101	107,557	125,032	124,320	121,593
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Return on Common Equity (%)	- -	- -	- -	- -	- -	- -	- -	-12.38	-18.68	-26.93	-51.7

	Sep'24	Dec'24	Mar'25
Total Current Assets	97,934	97,662	95,485
Accounts Receivable, Net	326	333	- -
Cash, Cash Equivalents & STI	96,222	96,080	- -
Inventories	410	335	- -
Total Current Liabilities	5,082	4,751	4,662
Payables & Accruals	- -	- -	- -
ST Debt	1,945	2,019	- -
Deferred Revenue	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	-150	-88	-124	- -	-391
2024	-118	-118	-129	- -	- -
2025	- -	- -	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	1,165	1,059	532	662	3,418
2024	285	560	693	824	2,362
2025	316	- -	- -	- -	- -

Genomictree Inc.

Growth Rates

(avg. rate of change)

Company Description

Capital Structure

Working Capital

Growth Rates

(avg. rate of change)

Quarterly Dividends Per Share

Year

Quarterly Earnings Per Share

Year

Quarterly Revenue

Year